169 related articles for article (PubMed ID: 25520106)
1. Gene microarray assessment of multiple genes and signal pathways involved in androgen-dependent prostate cancer becoming androgen independent.
Liu JB; Dai CM; Su XY; Cao L; Qin R; Kong QB
Asian Pac J Cancer Prev; 2014; 15(22):9791-5. PubMed ID: 25520106
[TBL] [Abstract][Full Text] [Related]
2. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2.
Zheng C; Yinghao S; Li J
Med Oncol; 2012 Jun; 29(2):815-22. PubMed ID: 21487968
[TBL] [Abstract][Full Text] [Related]
3. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
Gan L; Yin ZF; Li M
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):419-21. PubMed ID: 18581899
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.
Singh AP; Bafna S; Chaudhary K; Venkatraman G; Smith L; Eudy JD; Johansson SL; Lin MF; Batra SK
Cancer Lett; 2008 Jan; 259(1):28-38. PubMed ID: 17977648
[TBL] [Abstract][Full Text] [Related]
5. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
7. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
Tong da Y; Wen XQ; Jin Y; Liu ZW; Sun HY; Zhou FJ; Wu XY
Asian Pac J Cancer Prev; 2010; 11(6):1805-9. PubMed ID: 21338237
[TBL] [Abstract][Full Text] [Related]
8. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
9. [Literature-mining and bioinformatic analysis of androgen-independent prostate cancer-specific genes].
Li TQ; Feng CQ; Zou YG; Shi R; Liang S; Mao XM
Zhonghua Nan Ke Xue; 2009 Dec; 15(12):1102-7. PubMed ID: 20180422
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
11. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
[TBL] [Abstract][Full Text] [Related]
12. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells.
Yamasaki M; Nomura T; Sato F; Mimata H
Oncol Rep; 2007 Nov; 18(5):1145-53. PubMed ID: 17914565
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
14. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
15. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
17. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Ohlmann CH; Markert E; Gerharz M; Pfister D; Dienes HP; Engelmann U; Heidenreich A
Urologe A; 2008 Sep; 47(9):1218-23. PubMed ID: 18679646
[TBL] [Abstract][Full Text] [Related]
18. Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955.
Bisoffi M; Klima I; Gresko E; Durfee PN; Hines WC; Griffith JK; Studer UE; Thalmann GN
J Urol; 2004 Sep; 172(3):1145-50. PubMed ID: 15311059
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Qiao S; Pennanen P; Nazarova N; Lou YR; Tuohimaa P
J Steroid Biochem Mol Biol; 2003 May; 85(1):1-8. PubMed ID: 12798352
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of inhibiting the proliferation of prostate cancer by finasteride: a study using cDNA microarray].
Chen G; Geng J; Zhang YF
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1489-92. PubMed ID: 16061029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
